The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Proposed Mechanism of Action
Marizomib is a proteasome inhibitor derived from a novel marine-obligate actinomycete that belongs to the β-lactone-γ-lactam superfamily of proteasome inhibitors.1 In in vitro experiments, marizomib has demonstrated irreversible binding to and inhibition of all 3 proteolytic subunits of the human proteasome complex, resulting in inhibition of proteasome activity.2,3

Celgene acquired this asset from Triphase in 2016. Triphase continues to support marizomib’s development by remaining involved with the ongoing clinical trials.
marizomib by Disease State
marizomib in Solid Tumors
Phase 3
Newly diagnosed glioblastoma
View Trials Investigating marizomib in Solid Tumors
View Rationale for Clinical Development
Rationale for Clinical Development
In vitro experiments have revealed that marizomib inhibited proliferation and invasion and induced apoptosis in glioma cells.4 In addition, studies in rats demonstrated distribution of marizomib into the brain, and studies in monkeys demonstrated inhibition of chymotrypsin-like proteasome activity in brain tissues.4